Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2017 1
2019 1
2020 1
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean asako (245 results)?
Predicting severe inflammatory bowel disease: a risk matrix model based on the IBSEN III inception cohort.
Strande V, Hagen M, Lund C, Asak Ø, Bengtson MB, Boyar R, Detlie TE, Frigstad SO, Henriksen M, Holten KIA, Hovde Ø, Huppertz-Hauss G, Høie O, Johansen I, Medhus AW, Olsen BC, Opheim R, Perminow G, Ricanek P, Torp R, Valeur J, Vatn S, Aabrekk TB, Moum B, Høivik ML, Kristensen VA. Strande V, et al. Among authors: asak o. Scand J Gastroenterol. 2025 Jul;60(7):716-727. doi: 10.1080/00365521.2025.2512591. Epub 2025 Jun 8. Scand J Gastroenterol. 2025. PMID: 40483585 Free article.
Fatigue in Patients with Inflammatory Bowel Disease in Remission One Year After Diagnosis (the IBSEN III Study).
Holten KA, Bernklev T, Opheim R, Olsen BC, Detlie TE, Strande V, Ricanek P, Boyar R, Bengtson MB, Aabrekk TB, Asak Ø, Frigstad SO, Kristensen VA, Hagen M, Henriksen M, Huppertz-Hauss G, Høivik ML, Jelsness-Jørgensen LP. Holten KA, et al. Among authors: asak o. J Crohns Colitis. 2025 Apr 4;19(4):jjae170. doi: 10.1093/ecco-jcc/jjae170. J Crohns Colitis. 2025. PMID: 39527064 Free PMC article.
Fecal Microbiome Reflects Disease State and Prognosis in Inflammatory Bowel Disease in an Adult Population-Based Inception Cohort.
Hansen SH, Maseng MG, Grännö O, Vestergaard MV, Bang C, Olsen BC, Lund C, Olbjørn C, Løvlund EE, Vikskjold FB, Huppertz-Hauss G, Perminow G, Yassin H, Valeur J, Aass Holten KI, Henriksen M, Bengtson MB, Ricanek P, Opheim R, Boyar R, Torp R, Frigstad SO, Aabrekk TB, Detlie TE, Kristensen VA, Strande V, Hovde Ø, Asak Ø, Jess T, Franke A, Halfvarsson J, Høivik ML, Hov JR. Hansen SH, et al. Among authors: asak o. Inflamm Bowel Dis. 2025 Aug 1;31(8):2066-2080. doi: 10.1093/ibd/izaf060. Inflamm Bowel Dis. 2025. PMID: 40285477 Free PMC article.
Habitual intake of macronutrients and fermentable oligo-, di-, monosaccharides and polyols is not associated with irritable bowel syndrome-like symptoms in inflammatory bowel disease.
Zerouga I, Valeur J, Sommer C, Carlsen MH, Hagen M, Høivik ML, Kristensen VA, Opheim R, Hopstock LA, Strande V, Lund C, Boyar R, Asak Ø, Bengtson MB, Aabrekk TB, Hovde Ø, Huppertz-Hauss G, Detlie TE, Ricanek P, Frigstad SO, Stubhaug A, Aas AM. Zerouga I, et al. Among authors: asak o. Clin Nutr ESPEN. 2025 Jun;67:105-113. doi: 10.1016/j.clnesp.2025.03.005. Epub 2025 Mar 8. Clin Nutr ESPEN. 2025. PMID: 40064237 Free article.
Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial.
Goll GL, Jørgensen KK, Sexton J, Olsen IC, Bolstad N, Haavardsholm EA, Lundin KEA, Tveit KS, Lorentzen M, Berset IP, Fevang BTS, Kalstad S, Ryggen K, Warren DJ, Klaasen RA, Asak Ø, Baigh S, Blomgren IM, Brenna Ø, Bruun TJ, Dvergsnes K, Frigstad SO, Hansen IM, Hatten ISH, Huppertz-Hauss G, Henriksen M, Hoie SS, Krogh J, Midtgard IP, Mielnik P, Moum B, Noraberg G, Poyan A, Prestegård U, Rashid HU, Strand EK, Skjetne K, Seeberg KA, Torp R, Ystrøm CM, Vold C, Zettel CC, Waksvik K, Gulbrandsen B, Hagfors J, Mørk C, Jahnsen J, Kvien TK. Goll GL, et al. Among authors: asak o. J Intern Med. 2019 Jun;285(6):653-669. doi: 10.1111/joim.12880. Epub 2019 Apr 12. J Intern Med. 2019. PMID: 30762274 Free PMC article. Clinical Trial.
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.
Jørgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, Lundin KEA, Mørk C, Jahnsen J, Kvien TK; NOR-SWITCH study group. Jørgensen KK, et al. Lancet. 2017 Jun 10;389(10086):2304-2316. doi: 10.1016/S0140-6736(17)30068-5. Epub 2017 May 11. Lancet. 2017. PMID: 28502609 Clinical Trial.
Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials.
Jørgensen KK, Goll GL, Sexton J, Bolstad N, Olsen IC, Asak Ø, Berset IP, Blomgren IM, Dvergsnes K, Florholmen J, Frigstad SO, Henriksen M, Hagfors J, Huppertz-Hauss G, Haavardsholm EA, Klaasen RA, Moum B, Noraberg G, Prestegård U, Rydning JH, Sagatun L, Seeberg KA, Torp R, Vold C, Warren DJ, Ystrøm CM, Lundin KEA, Kvien T, Jahnsen J. Jørgensen KK, et al. Among authors: asak o. BioDrugs. 2020 Oct;34(5):681-694. doi: 10.1007/s40259-020-00438-7. BioDrugs. 2020. PMID: 32965617 Free PMC article. Clinical Trial.
Low Surgery Rates in Early Crohn's Disease: Results from a Prospective Population-Based Inception Cohort-The Inflammatory Bowel Disease in South-Eastern Norway III Study.
Lund C, Strande V, Hagen M, Bengtson MB, Boyar R, Detlie TE, Frigstad SO, Medhus AW, Henriksen M, Holten KIA, Hovde Ø, Huppertz-Hauss G, Johansen I, Olsen BC, Opheim R, Pallenschat J, Perminow G, Ricanek P, Torp R, Ystrøm CM, Høie O, Asak Ø, Vatn S, Aabrekk TB, Kristensen VA, Høivik ML. Lund C, et al. Among authors: asak o. Inflamm Bowel Dis. 2025 Aug 1;31(8):2173-2183. doi: 10.1093/ibd/izae297. Inflamm Bowel Dis. 2025. PMID: 39699202 Free PMC article.